Pancreatic Enzymes Market Size, Share, Growth, and Industry Analysis by Type (Pancreatin Powder and Pancreatin Pellets) By Application (Laboratories and Medical), Regional Insights, and Forecast To 2032

Updated On: 22 April 2024

Pancreatic Enzymes Market REPORT OVERVIEW

• 

• Request a Free Sample to learn more about this report

The global pancreatic enzymes market size was USD 160.8 million in 2022. As per our research, the market is expected to reach USD 320.8 million in 2028, exhibiting a CAGR of 12.2% during the forecast period.

The pancreatic enzymes market refers to the global industry involved in the production, distribution, and sales of pancreatic enzyme products. Pancreatic enzymes are naturally occurring substances produced by the pancreas that aid in the digestion and absorption of nutrients in the small intestine. They play a crucial role in breaking down fats, proteins, and carbohydrates into smaller molecules that can be easily absorbed by the body.

Pancreatic enzyme products are commonly used as pancreatic enzyme replacement therapy (PERT) in individuals with exocrine pancreatic insufficiency (EPI). EPI is a condition characterized by insufficient production or secretion of pancreatic enzymes, often caused by chronic pancreatitis, cystic fibrosis, or pancreatic cancer. PERT helps restore the normal digestion process by supplying exogenous pancreatic enzymes.

The pancreatic enzymes market has experienced significant growth in recent years due to the increasing prevalence of EPI and related disorders. Factors such as a rise in the aging population, improved diagnostic techniques, and increased awareness about pancreatic disorders have contributed to the expanding market. Additionally, advancements in drug delivery methods and the development of novel enzyme formulations have further fueled market growth.

COVID-19 Impact: Supply Chain Disruptions to Limit the Market Demands

The pandemic led to disruptions in the global supply chain, affecting the production and distribution of pharmaceutical products, including pancreatic enzymes. Lockdown measures, travel restrictions, and reduced manufacturing capacities in different regions have resulted in supply chain challenges, causing shortages or delays in the availability of pancreatic enzymes. COVID-19 has raised awareness about the importance of maintaining overall health, including digestive health. Individuals with pre-existing conditions such as pancreatic insufficiency may have heightened concerns about their susceptibility to the virus. This increased awareness, coupled with the potential for gastrointestinal symptoms associated with COVID-19, may have led to an increased demand for pancreatic enzymes.

LATEST TRENDS

"Growing Awareness and Diagnosis to Augment the Market Growth"

The pancreatic enzymes market has witnessed technological advancements aimed at improving the efficacy and convenience of pancreatic enzyme supplements. For instance, new formulations have been developed to enhance enzyme stability and maximize their activity, ensuring better digestion and absorption. Awareness about pancreatic insufficiency and related disorders has been increasing among healthcare professionals and patients. This has led to improved diagnosis rates and a higher demand for pancreatic enzyme supplements. The pancreatic enzymes market has been witnessing consolidation with mergers and acquisitions among key players. Larger pharmaceutical companies are acquiring smaller companies to expand their product portfolios and gain a competitive edge in the market.

Pancreatic Enzymes Market Segmentation

• 

• Request a Free Sample to learn more about this report

• By Type Analysis

By type, market is segmented into pancreatin powder and pancreatin pellets. The pancreatin powder type segment will dominate the market in the coming years.

• By Application Analysis

Based on applications, the market is classified into laboratories and medical. The laboratories segment will lead the global share through 2028.

DRIVING FACTORS

"Increasing Geriatric Population to Push the Market"

The increasing incidence and prevalence of pancreatic disorders such as chronic pancreatitis, pancreatic cancer, and cystic fibrosis are driving the demand for pancreatic enzyme replacement therapy (PERT). These conditions often result in exocrine pancreatic insufficiency (EPI), where the pancreas fails to produce enough digestive enzymes, leading to malabsorption. The need for pancreatic enzymes to manage EPI is a significant driver for the market. There is a growing awareness among healthcare professionals and patients about pancreatic disorders and their management. Improved diagnostic techniques and screening methods have led to early detection and diagnosis of pancreatic diseases, resulting in an increased demand for pancreatic enzyme therapies. Early intervention and treatment contribute to the market growth. The global population is aging, and the elderly population is more susceptible to pancreatic disorders. Age-related changes in the pancreas can lead to EPI and other pancreatic diseases. As the elderly population grows, the demand for pancreatic enzyme replacement therapies is expected to increase, driving the market.

"Favorable Reimbursement Policies to Boost the Market Demands"

Advances in pharmaceutical formulations and drug delivery systems have improved the efficacy and convenience of pancreatic enzyme replacement therapies. Innovations such as enteric-coated capsules and microsphere-based formulations enhance enzyme stability, bioavailability, and patient compliance. These advancements attract both healthcare providers and patients, contributing to market growth. Adequate reimbursement policies and insurance coverage for pancreatic enzyme replacement therapies play a crucial role in market growth. Patients are more likely to seek treatment and adhere to therapy when their financial burden is reduced. Favorable reimbursement policies encourage market adoption and drive the demand for pancreatic enzymes. Pharmaceutical companies and research institutions are investing in the development of novel pancreatic enzyme products. Ongoing research aims to improve the stability, potency, and patient compliance of these therapies. Continuous advancements and new product launches in the market stimulate growth and expansion.

RESTRAINING FACTORS

"Limited Awareness and Diagnosis to Slow the Market Growth "

The development and commercialization of pancreatic enzyme products require compliance with stringent regulatory requirements and approvals. The extensive regulatory process can be time-consuming and costly, posing a barrier to entry for new market players and potentially limiting the availability of innovative products. Pancreatic enzyme replacement therapy (PERT) is the standard treatment for individuals with exocrine pancreatic insufficiency (EPI). However, the cost of PERT can be high, especially for long-term therapy. The high cost of treatment can limit access for patients, particularly in regions with limited healthcare resources or inadequate insurance coverage.

Pancreatic Enzymes Market REGIONAL INSIGHTS

• 

• Request a Free Sample to learn more about this report

"North American Market to Grow Exponentially with the Forecasted Period"

North America dominates the pancreatic enzymes market and is expected to continue its leading position. The region has well-developed healthcare infrastructure, advanced diagnostic technologies, and a high prevalence of pancreatic disorders such as chronic pancreatitis and cystic fibrosis. Additionally, a large patient population, increased healthcare expenditure, and favorable reimbursement policies contribute to the market growth in this region.

KEY INDUSTRY PLAYERS

"Key Players Focus on Partnerships to Gain a Competitive Advantage "

Prominent market players are making collaborative efforts by partnering with other companies to stay ahead in the competition. Many companies are also investing in new product launches to expand their product portfolio. Mergers and acquisitions are also among the key strategies used by players to expand their product portfolio.

List of Market Players Profiled

• Shenzhen Hepalink (China)
• Nordmark (Germany)
• Sichuan Deebio (China)
• Sichuan Biosyn (China)
• Chongqing Aoli (China)
• American Laboratories, Inc. (ALI) (U.S.)
• Spectrum Chemicals (U.S.)

REPORT COVERAGE

The market research study examines the worldwide market in detail, focusing on important elements such as leading players, product/services or type, and leading end-use applications. Aside from that, the research analyses major advancements and provides insights into lighting market trends. In addition to the causes indicated above, the paper includes a number of other factors that have contributed to recent growth.